Survival after myocardial infarction in rats: captopril versus losartan  by Milavetz, James J. et al.
714 
EXPERIMENTALSTUDIES ___ _--_ _.-.--- ___-. 
Survival After Myocardial Infarction in Rats: Captopril 
Versus Lmartan 
JAMES J. MILAVETZ. MD. THOMAS E. RAYA, MD. CYNTHIA S. JOHNSON. BS. 
EUGENE MORKIN, MD. STEVEN GOLDMAN. MD. FACC 
wives. This study solyht lo compare the elects of 
w enzyme iabibitioa versus aItgiotcOSi0 II 
rrae(or #rdulc ai mvivml in nts with mywanlhl ink&m. 
Ik+umd 'Ibc &cls d specific wapptik angiatensin 
rrtcptor bkki4 mgtm 011 ~~nival dkf q yoardii iofarctioo 
we- 
The use of angiotensincMlverting enzyme mhihition is now 
established therapy for patients with chronic congcztivc heart 
failure (l-3) and for patients with systolic dysfunction after 
myueardial infarction (45). Angiotensin-eonverting enzyme 
inhibitors a!so appear to decrease the incidence of recurrent 
myoaudial infarction. unstable angina and sudden death (2- 
4). Although these beneficial effects are well ducumented. the 
mechanism of action of these bgents is not clear. It is generdlly 
believed that angiotensin-converting enzyme inhibitors exert 
their cardiac ellects primarily by decreasing afterload and 
pre.load through inhibition of the conversion of angiotensin I 
to angiotcnsin II (6). The mechanisms of action ofangiotensin- 
converting enzyme inhibitors may be more complex than 
simply aftertoad reduction. because laboratory (7) and clinical 
studies (2.8) how that a relatively pure afterload-reducing 
agent, hydralazine, is less beneficia! than angiotensin- 
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converting enzyme inhibitors. In the rdt coronary artel! liga- 
tion model of heart failure, captopril decreased left ventricular 
end-diastolic pressure. increased venous compliance and atten- 
uated left ventricular dilation, whereas hydralazine had none 
of these efiects (7). In addition, because serum angiotensin- 
converting enzyme inhibitor activity is not elevated during the 
chronic compensated phase of congestive heart failure, it is 
dilhcult to argue that blocking the effects of angiotensin- 
converting enzyme inhibitors would result in hemodynamic 
benefit (9). Thus, angiotensin-co.lvening enzyme inhibiton 
may exert beneficial effects in addition to those predicted from 
the pharmacologic actions of these agents on the plasma 
renin-angiotensin system. Potential explanations for the mech- 
anism of action of angiotensinconverting enzyme inhibitors 
are their effects on the kinin and pro..Iaglandin systems (6,9- 
14). 
Lusanan is a nonpeptide angiotensin II receptor blocker 
that lack\ bradykinin-potentiating effects. When the hemody- 
namic effects of losiirtan and captopril were cclmpared in 
experimental hcan failure, both agents decreased left ventric- 
ular end-diastolic pressure, decreased left ventricular end- 
diastolic volume and increased venous compliance without a 
change in heart rate (IS). In addition, a recent report (16) 
showed that both cnalapril and losartan equally attenuated the 
development of myocardial fibrosis in the noninfarcted rat left 
ventricle. 
Because both captopril and losar~an improved leti ventric- 
ular hemtxlynamtc variahks in the rat model of heart failure 
After myocr;rdial infarction. and captopril has been shown to 
improve long-term survival. the prc?rnt study was designed to 
examine the effects of losartan on survival. The hypothesis was 
that there would LX no dizerence in survival in rats treated with 
losartan or captopril after cxperimcntal myocardial infarction. 
Methods 
Coronary ligatiw model. Mak Sprague-Da&y tats ( 172 
to 275 g) underwent coronary artery ligation using techniques 
similar to those described previously (7.15). The study was 
perfnrmcd in an AAAl AC-accrediicd facility with approval 
from the animal use committees of the Tucson Veterans 
Aliairs Medical Center and the University of Arizona. After 
coronary ligation. rats were returned to their cages and ran- 
domly assigned to treatment with losartan (2 @liter drinking 
water) or captopril(2 fliter drinking water) using a balanced- 
block randomization process. Previous dose-ranging studies 
(15) showed that losartan shifts the log-pressure response 
curve to angiotensin II and that in these doser losarran and 
captopril have similar hcmodynamic effects in rats with heart 
failure. The rats were allowed acress to their respective 
drinking water and standard rat chow ad libitum. Rats were 
housed in clear polyethylene cages not exceeding two rats per 
cage crud were placed in individual cages when tLy grew to 
>500 g. Cages assigned IO losartan and to captopril were 
placed alternately on tlhx cage racks. All rats were housed in a 
single room of the animal facility with a 12-h light-dark cycle 
and independent ventilation. temperature and humidity con- 
trol. Animals wcrc weighed monthly and observed for I year. 
Ten to 14 days after operation. rats were dnesthetiid with 
methoxytlurane, and a nine-lead electrocardiogram (ECG) 
with six limb leads and three chest lear’.s was recorded. Only 
rats with ECG evidence of moderate to large myocardial 
infarctions on the oasis of dmribed criteria (7.1517) were 
continued in the study. 
Cages were inspected for dead animals daily. The date of 
death and the animal’s weight were noted. A postmortem 
examination was petformzd. and the lungs were inspected for 
gross signs of consolidation. The lungs and heart were placed 
in formalin for subsequent necropsy studies. 
Patbdogk tit&es. The formalin-fixed !ungs were dis- 
sected from the heart and examined for area of consolidation. 
A scoring system for evidence of infection was applied IO each 
specimen (IZ). Myocardial infarct size was measured in all 
animals using the endocardia! circumference technique de- 
scribed previously (7.15). As m previous work. rats were 
considered to have a moderate to large infarction when &!W 
of the left ventricular surface area was occupied by fibrous scar 
tissue (18). Group stratification was confirmed at postrrttxtcm 
examination by quantitative left ventrkular histopathologii 
studies. 
tkmdy~& * Left ventricular function was eval- 
uated in the surviving rats at the end of the trial. In brief. 
rats were anesthetized with rnethoxyflurane. and a l-mm 
micromanometer-tipped catheter (Mdla~ Instruments) was 
inserted into the right carotid artcr)l. The cathctcr W;FI ;~d- 
vanccd into the aorta and then into the left vcntriclv utilizing 
constant prcssttrc monitoring. 1 I.; xcro-prcxure hascline was 
ohtaincd hy placing the prcssurc sensor in 37-C saline More 
mcasurcment> After initial rccardingr ucrc thtainsd. rhc 
cathetrr was cxtcriorized to the midccrvical region. and the 
animals were allowed to recover from anesthesia and opera- 
tion for at least 4 h hcforc hemodynamic mcasurcmcnh were 
obtained. 
Stressed kfi wntriculsr performance. After completion of 
haselinc hemodynamic mcasuremcnts. the animah urre an* 
thctized with thiobutabarbital (Ardrcw Luckwcxd Ashatrs). 
Approximately 4t) min was alknveJ for complete anesthesia 
hefore measurcmcnts of strtiscd left ventricular pumping 
capacity were obtained. The left fcrnlual rrtq wah then 
exposed. and a O.M-mm thermistor micrr~obe (Columbus 
Instruments) was advanced to the tieruling aorta. The 
contralateral femoral artery and the superior vena cava were 
canulated with PE-50 tubing for measurement of mean arterial 
pressure in the descending aorta and right atria! pressure. 
Thermodilution cardiac output and heart rate uere meawred 
simultaneously for calculation of stroke volume. To measure 
stressed left ventricular prcssurc dcvelopmcnt. the rat was 
intuhated with a X-gauge Angi~th catheter and ventilated 
with a volumecycled respirator f Harvard Apparatus). A mc- 
dian stemotomy was then performed and a 14 silk tie was 
positioned around the aorta. A 2- to f-cm piece nf polyethyl- 
ene tubing (1.75 mm inside diameter) was placed over the tie 
and used as au occlusion device. The aorta was occiuded for 2 
to 3 s to produce &volumetric (except for coronary Row) 
contractions. The peak left ventricular pressure developed was 
detennincd by measuring the difference in peak systolic and 
enddiastolic prwures after 5 stable beats. 
Irolrud ldt vatriemhr pmsam -After 
completion of all measurements. potassium chloride was in- 
jected rapidly into the right atria1 catheter to arrest the heart in 
diastole. Pressure-volume data were recorded using methods 
dexrihed carlier (7.17.19). Briefly. the heart was rapidly 
removed. ani the right ventricic was inctud. A double-lumen 
catheter attached to a pressure transdtker (Statham 23lJ. 
Gould) and an infusion pump (Sage 511. Orion Research) 
were passed into the kft ventricle and secured with an aortic 
ligature. The atrioventricular groove was identified. and a 
ligature was pawd around the heart and tied to isolate the left 
atrium from the left ventricle. After gentle aspiration of the 
left ventricular cavity to remove any residual blond and to 
reduce the prmre to -5 mm Hg. normal saline was infused 
at l ml/min into the suspended kft ventricle while prewre was 
recorded. saline was infused until the pre?;sure increased lo 
Jo mm Hg. and vdume was determined from the infusion rate. 
Three curves were obtained from each ventrick within IO min 
of the cardiac arrest. and the averaged values of vdume at 
given pressures were reported 
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Figuurr 1. tiplan-M&r cuncs in ~1s with a mtdcrale IO 
Ixrgc mfarcllon ~rratrd with captopril and lmartan (2 g/liter 
drinkq water each). One-year median survival in caytcb 
pril-created rats uas X1 5 da)3 YC~WC ?.Wb daa lmnan- 
irel!ed ruts (log rank p = MM! 
~M&ms. The time constant of left vcntriculnr rclax- 
ation (tau) and chamkr stiffness wcrc tit IO the i’ollowing 
equations using published techniques (IO): 
dP/di = - a(P - PBI. 
wkrc PR is the intercept of pressure at I = 0; a is calculutcd hy 
tk least-squares m&ho4 (r > 0.99). and tau -f - l/a. 
where K, or chamkr stiffncsq. is the slope of the relation 
lo P = &V + In PO- 
M B cavity vdlwWl vdusrr. Ventricular 
cavity volume at a distending pressure al 10 mm Hg ~‘3s 
determined from the passive pressure-volume relation. Left 
ventricular wall bolumc. V,,. was determined from the mass of 
the left ventricle (LV). such that V,, = LV mass (g)1l.U6. where 
1.06 is equal to muxle density. IXs relation assumes that 
veabicular muscle is incompressible. 
btkticd e Tk Student 1 test was used to test for 
differences in all hcmodyna~~~ic and remodeling measurements 
as well as weight and age at time of myocardial infarction 
between the two treatment groups. Because not all rats were 
observed until natural death, survival analysis was used to 
adjust for these censored observations. The survival curve for 
each treatment was dctermi;led using the Kaplan-M&r 
method. Comparisons of lhc survival distributions between 
bartan- and captopril-treated rats were performed by a 
log-rank test (20). In planning the study, sample size calcula- 
tioos MIT pcrfonmd with the intent to detect a 2U% differ- 
cooe (i-e- 40% vs. 20% for I -year survival) ktwcen treatments 
with a two-sided significam~ level of 0.05 and IJO% power. 
Because pc&ik differences in rates of thoracic infections 
Could Wrltriitc to an alteration in group survival. an addi- 
tional log-rank analysis was done that cemorcd data fnrm 
animala with a tbofa& infection score of grade 3. The &&ion 
to annlyle the data ansorcd far lung infections was made 
-Iy, kfofc initiation of the study. 
Results 
A tatal of 237 animals were entered into the study; I19 were 
randon,& to captopril treatment and I18 lo losartan treat- 
ment. In the captopril trcatmcnr group. 41 rats died before the 
ECG was recorded, I rat died during the ECG anesthetic 
period. and 31 rats had a small f<IU%) infarction by ECG 
criteria. In the losartan treatment group. 45 rats died kforc 
the ECG was recorded. I died immediately after the ECG, and 
21 had a small infarction by ECG criteria. All rats that died 
kforc the ECG was recorded died within 48 h after coronary 
ligation. Rats with ECG evidence of a small myocardial 
infarction were excluded from further analysis. Of the rats with 
ECG evidence of a small infarction, only one had a scar 
detectable at autopsy examination. In contrast, no rat with 
ECG evidence of moderate to large myocardial infarction had 
a grossly normal left ventricle. 
Thus, 46 rats with a moderate or large myocardial infarction 
were treated with captopril. and 51 rats with a mockrate to 
large myocardial infarction were treated with bartan. There 
were no significant diffcrenccs in body weight (p = 0.684) or 
age at the time of myocardial infarction (p = 0.229). Infarct 
size in rats treated with captopril that died duling the trial was 
37 2 4% (mean 2 SD) (range 18% to 49%) versus 38 z 4% 
(range 19% to 56%) in ratx treated with losartan. In both 
treatment groups, there was one rat with an infarct size ~20% 
and one rat with an infarct size >SO%. 
fhrvivd data ‘Ihe survival cu~cs for rats with a moderate 
to large infarction that survived *. til the ECG are shown in 
Figure 1. Although there is no statistically significant diicrencc 
in median survival bchvccn the two treatment groups-201.5 
days for captopril versus 236.0 days for losartan (p = 0.Of16)- 
tk survival curve for the barian-treated rats is above that for 
tk captopril treatment group starQng within 2 weeks of 
@tonary ligation. When the analysii included all rats that died 
within 48 h of tk infarction, median survival in tk cap&@- 
treated group was 34.0 days versus 54.0 days for lcwartan 
treatment (p = 0.132). 
Among rats wirb iI mtdcratc IO lrrrgc inftirrtlo I Ihilt hur- 
vivcd until the ECG w;14 rccordcd. three rat\ :P the L;lrtun 
group had class 3 lung consolidation. a grarling consistent with 
pneumonia (see Methods). Thcrc wcrc no clash I or cb\\ 2 
lung consolidntions in the 1osani.m group. No ldfs in the 
captopril group haJ lung consolidation. In the Iosartan-treated 
rats with lung consolidation. the Infarct sizes urrc JYG. .lY’; 
and 4HCi. respcctivcl!. Thc~! infarct Grcs wcr? in the upper 
IUC; of infarct Lzc for this study. Bccausc lung conx)tidution 
wa5 not cvcnly distrihutcd between the two proups. data from 
thcsc three animals wc’rc not censored for the primary analyis. 
Had these three rats hcen considcrcd ccnsorcd. the median 
survival for captopril-trcatcd rats would hc zOl..i daya. YL‘M\ 
243.11 for losartan-treated rats (p = O.UY:). 
Hemodpmic variables and kfl vcnfricubr retnodding. 
Hemcenamic and left ventricular remodeling mcarurcmcnts 
wcrc obtained at I year in the surviving rats. When captopril- 
and Iosartan-trcatcd rats were romparcd. ihcrc were no d+- 
fcrcnces in left ventricular weights (I.073 : OH vs. YM ? 
213 mg), left ventricular systolic prrs\ures (10Y Z IY vs. YS ? 
26 mm Hg). left ventricular end-diastolic pressure (II + 7 vc. 
I I z Y mm Hg). dP/dt (5.271 ? 8M vs. 4.H3fi 2 I.276 mm 
Hgk), cardiac index (31 f 57 vs. 27h ? 5X nl:kg per mink. 
time constant of relz:ation (20.2 + 3.4 1s. IY.4 Z 4.1 ms). 
stroke volume index (I.17 ? U.2U vs. U.Y7 + U.3 ml,‘kg per 
min). chamber stiffnclr constants (2.35 z 0.71 vs. LXI ? 0.98). 
chamber volume/wall volume (0.r) )_ 0.21 vs. l.UY 2 U.40). 
ventricular length I17 S +_ 1l.Y vs. 18.7 z I .S mm), ventricular 
diameter (9.49 2 0.78 vs. lU.Ul f 1.M mm). wall thickness 
(2.22 ? 0.24 vs. 2.03 2 0.21 mm) or myocardial infarction size 
(31 + 45 vs. 38 -t 74). The only differences were ;n increase 
in heart ratr (2Y3 -t 19 vs. 266 2 1.S bcatsimin. p = U.OlK) and 
a dccreascd pcdk dcvelopcd prcssutc (153 -+ $1 vs. i8U I 
I6 mm Hp. p = U.U24) in the Itirtan-trcatcd rats. 
Discussion 
The prewnt study confirms that mortality ic increased in 
rats with heart failure after moderate IO large myocardial 
infarction caused by coronary artcry ligation. WC also showed 
that thcrc was no Jiffcrcncc in survival with specific angiotcn- 
sin Ii receptor hlockadc with losartan versus angiotcnsm- 
converting cnqmc inhibition with wptopril. Indexes of mytr 
ciirdial function and left ventricular geometry. obtained at I 
year in surviving rats. showed no Mcrcnccs bctwccn losartan- 
and captopril-treated rat.. No differcnccs wcrc noted in heart 
weight, left ventricular pra5ures. dP/dt. cardiac index. time 
constant of r&cation or left ventricular volume and dimen- 
sions. There was an increase in heart ntc' and a decreax in 
peak devclopcd pressure in infarcted rats trcatcd with losartan. 
Although other studies have been pcrformcd to study the 
hemodyncmic di5ercnccs resulting from specific angiotcnsin II 
receptor blockade VCRUS angiotensin-converting enzyme inhi- 
bition. to our knowledge this is the first to examine sutiival. 
NU!dIOllSI- hIa This study was designed with 
mal mortality as the primary cod point. We presented both 
the ccnulrcd and tk 1 unnvwrcd datd htx'auu: the tin:+. in 
which animal< with clvcrt lung ccmcc,hdation usrc ccnwrcd. 
rchullcd in a ~ignlticilnl incrcazw in median uunivrl in the 
I(n&.n group. A total of thrrr rats in the I;Mrtan group and 
none in the ctiptop~;;I grclcp had lung consolidation. Bccausc 
only three rats m the IthanLin group and no rat\ in the 
i;iptopril grlwp cmld fwtcntL1~ he ccnwrcd on the h& of 
lung mfcctkrn. cenujring. whrh dstumcs a ran&m t*currcncc 
bclwccn grl)Ups. could k mtcrprctcd a\ Gati\lic’all! inapprcb 
priatc. ‘rhr: uruplc SIX in the prcscnt study and the incidence 
(,I inkction ucrc IW small to dctcrmine whrthcr the Jistrihu- 
;ion elf rat\ with mfccticbn In the ltnartan group ~‘4% hiokrpically 
G~nifbnt. When lwg nrnwlidation W;I\ cxamincd prcviousl! 
m rdt\ with infurctlon. the mcidrnrc wat not a function of 
rnfdrct rirc (IN). rlthtiq!h in our wJII rst\ with lung conwl- 
rdatlon had infarct Grcs in the uwr Ill’; elf int’arct WCS. Our 
intcrprstatic)n of thi\ oknation I\ th;lt lun:: consolidation. 
which i\ rare in health? rFt\. occur+ in rat\ dftcr mycsrihl 
infarct& and the incidcncz ma! hc mcrw&d in rbth with 
larger infarction\. 
Cmpmrison with previous work. llwc arc few pubhstwd 
animal studics conccming su~+al after m~~rardial infarction. 
Tbc present study design W;LT based on ttc original capqril 
survival study by Pfcflcr ct al. (IX). with th major di5erem 
that treatment wac initiated cm the day of the infarction: m the 
earlier study treatment UP\ PIV.G! tin day 1-L III h,th stud& 
the dtw of captopril was the same. 2 plrtcr drinking water. In 
the study by Pfe5cr r’t al.. captopril imprtBsd wni+al In rat% 
with moderate-sized Infarctions. and thrrc was no sipnikant 
di6erence but ;I trend toward improved survival in rats with a 
large infarction. The median sunival in the mtdcr~tc and large 
infarct groups trcatrd with captopril was 32Y and IHI days. 
rcspaztivcly. If the I4 days before tk initratwn of therapy is 
subtracted from the sunSal repnrtcc’ in our study. the median 
survival of bl.5 day3 for captopril-lrcatrul rats with a modrr- 
ate to large irlfarction in our stud! is comparable. In our Vial. 
after elimination of the rats that died heforc the ECG. U, rats 
were trc*ated with captopril and 51 with losartan curllpared 
with U rats with a mcdrratc infarction and 37 with a large 
infarction as$ned IIJ captopril rn the earlier SIUU). Thus. 
&%pite Ihe di6cremr in study &sign and ?crnLn the 
survival data with captc,prii in hrth of thcx studm arc similar. 
In a second and morr rerrnt huGal study of rats in Han 
failure treated with two duscr oi anpiotrmincr)nvcning en- 
zvms inhibition, the mortality rate at I jcar aas ti.4’i for rats 
$ilh a modcrate infarction and IOOC; for rats kth a large 
infarction (:I). Thus it is clear that untreated tats with a 
modcratc to large infarztion have a \cry poor p-s. 
In the prrwnt study. thcrc were no di6crenccs in any index 
of left ventricular remodeling. including data on ventricular 
geometry and wall thickness. in surviving rats treated with 
Imartm .)r captopril. In addition. tllrre were no di6ercnrcs in 
systolic function. diastolic function or infarct size anXMlg 
surviving rats. Although the present Study Y;ts nul dri* 
spccificCy to examine remcdelin~ lksc data suggest Ibat 
tkrc were 110 dikrenaz in remodeling among lhe sun’kg 
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rats treated with captoprii or Iosartan after I year. A similar 
conclusion was reached when infarcted rats verc treated for h 
we& with enalapril or losartan and there wcrc no dillcrcnccs 
in cardiac ttypertropby. minimal coronary vawular Gstance 
or mpcardial intcrstittal tihrosis (16). 
Coptopril and losartan may have divergent ckls on kinin 
and pmstaglandin metabolism ( IO.1 I). Htnvcver. Iosattan has 
no bradykinin-potentiating eKeets and it Is unclear whether 
losartan affects the prostaglandin system (22-3)). Although if 
has been postulated that the beneficial effects of angL.tensin- 
converting enzyme inhibitors in !he treatment of heart failure 
may be caused in part by elevation of bradykinin or prostag- 
landin levels, our data suggest that spcc~fic blockade of angio- 
trnsin II is primarily responsible for the survivsl hcncfits 
attnited to angiotensin-converting cruymc inhibitors in the 
rat model of heart failure. 
Although this survival study compared angiotensin- 
cottvert+g enzyme inhibition with direct angiotrnsin II reccp 
tor blockade, earlier work from our laboratory showed that the 
bemodynamic cffec*s of losaltan and captopril in rats with 
heart failure after myocardial infarction were similar (15). 
Although the conclusions rcachcd here apply only to the doses 
of agents used, the justiftcation for testing these doses is that 
the captoptil dose has been used in previous studies (7,lg). and 
the losartan dose has similar hemodynamic eKccts as noted 
before (15). 
Tim@ of tmtmrot. Although the original studies exam- 
ining treatment with angintemin-converting enzyme inhibitors 
after myocardial infarction were done after healing of the 
inlarct. earlier treatment rcgi;;lens are now being favored. 
When Legun 14 days after experimental infarction. captopril 
has been shorn (21) to affect ventricular remodeling favorably 
and to pm+ong survival in rats. Other work using the rat 
infarction model has eonfirmed that angiotensin-con\Mng 
enzyme inhibition is comparable to Iosartan when started 2 to 
3 w&s after myocrrdial infa;ctti (25). Clinical trials also 
have shown a benefit when treatment is started 3 to 9 days after 
infarction (4). and data now show that initiating treatment 
within 24 h of an anterior wall infarction improves survival 
m 
SW& limkatiomt. The lack of a placebo arm in the present 
trial has to be adressed. In designing the prrscnt study. our 
intention will to compare the eKects of specific angiotensin II 
blockade with those of angiotensin II converting enzyme 
inhibition in nts with heart failure after a moderate to large 
infarction. Inclusive of operative rnoriality. -35% of rats 
undergoing coronary ligation in our laboratory have moderate 
to large myazrdial infarction. Operation was performed in 
237 rats to obtain 97 animals for the present study. In planning 
the study, the sampk size calculations were performed with the 
intent to detect a 20% diKerena between treatments with a 
two-s&d sigificmce level of 0.05. Had we chosen to include 
a plXh3 m. to achieve that level of SignifKance and power 
with three treatment arms would have required us to operate 
011 !M4 raEs &aupc the beneficial eKects of angiotensin I1 
eomf&ng ettync inhibitiin are already well defined in both 
rats and woplc after myocardial infarction. WC concluded that 
thcrc WI no compelling rc;islm to warrant a placeho heart 
failurr group. 
When a study shows no diKcrcncc bc Wccn g~ups, the iksuc 
of statistictil power must also bc addressed. The study was 
designed to have a statistical power oi #I%; thus. the possihil- 
;ty of a hcta error. or a failure to dl* * . . a diKercnce between 
two treatment groups. such as hetwccn lclrartan and captopr;l. 
when a diKcrencc actually c’xisls is 2W.. Thus. the power of the 
study was adcqudte to detect a diffc .mcr between the two 
drugs with 80% contidcnce. 
Al:hough it is new established from d:linical sMes that 
survival after anterior wall myrxardiat mlrction is imprmcd 
with trcatinent with angiotcnsinconverting enzyme inhibitors 
iniliatcd immediately after infarction (26). true firstday thcr- 
spy is not feasihle in our rat model of postinfarction heart 
failure. Even though lcnartan or captopril WAS available in the 
rat’s dr%king water. we ohservcd that for the first I to 2 days 
after Lxlronary artery ligation. rafs do n?t a:at or drink. For 
protml considerations. therefore. our primary survival anal- 
pis was for those rats thal lived >48 h at:cr %bronary rnery 
ligation. 
Our study showed no differences ir: any indexes of left 
ventrirvlar remodeling among the surviving rats at I year. but 
to conclude that no diKerences existed may be misleading. 
Bec3U~C so few :;,s survived to undergo hemodynamic and 
remrdcling studies, we lacked statistical power to exclude a 
difference in remodeling. However, the major purpose of our 
study was to examine sutvival rather than rel.mdeling. 
Comdpskms. In the present model, there was no diKcrence 
in survival bctwccn captopril and lhrtan. Ltiust the origi- 
nal captopril survival study in rats (IS) accuralQ prcrlilzted the 
beneficial outcome of the clinical studies, it is reascnable to use 
the present data as the rationale for a clinical survival trial of 
angiotensinconvcrting enzyme inhibition versus direct anpie 
tensin II receptor blockade. 
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